Sionna Therapeutics, Inc. (SION) News
Track canonical SquawkNews coverage tagged to SION, Sionna Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Sionna Therapeutics Is Maintained at Neutral by Wedbush
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:47 PM UTC
L
SION: AscenSION CF phase IIa trial will test SION-451 plus SION-2222 in CF, starting Q1 2027
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to a dual combination strategy with SION-451 plus SION-2222. The AscenSION
NEWS | Sep 14, 2026, 11:48 PM UTC
L
SION: AscenSION CF will test SION-451 + SION-2222 as a novel dual therapy for cystic fibrosis
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to the SION-451 + SION-2222 dual combination. The upcoming AscenSION CF tri
NEWS | Sep 14, 2026, 10:06 PM UTC
L
SION: Dual combination SION-451 + SION-2222 showed promising safety and efficacy, advancing to Phase 2a
Post hoc analysis of the PreciSION CF Phase 2a trial revealed that removing confounded participants showed evidence of NBD1 target engagement, with a mean sweat chloride reduction of up to -8.6 mmol/L. The preferred dual
NEWS | Sep 14, 2026, 08:34 PM UTC
L
Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development
By Elias SchisgallSionna Therapeutics will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment.The company said Monday that it will advance a combination of SION-451 and SION-
NEWS | Sep 14, 2026, 08:28 PM UTC
L
Sionna Therapeutics terminates Caroline Stark Beer as Chief Business Officer; Elena Ridloff named Chief Business Officer
Sionna Therapeutics terminated Caroline Stark Beer as Chief Business Officer effective September 15, 2026, and reassigned executive roles with Elena Ridloff assuming Chief Business Officer on September 16, 2026.Original
REGULATION | Sep 14, 2026, 08:13 PM UTC
L
SION: SION-451 + SION-2222 will advance to Phase 2a after analysis supports NBD1 activity
Post hoc analysis of the PreciSION CF trial revealed confounding factors but supported NBD1 biological activity, leading to the advancement of SION-451 + SION-2222 into a Phase 2a trial. Cost-saving measures, including a
NEWS | Sep 14, 2026, 08:12 PM UTC
L
SION - Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
SION - Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
NEWS | Sep 14, 2026, 08:01 PM UTC
L
Sionna Therapeutics (SION) investigated stock drop by Robbins LLP
Robbins LLP reminds Sionna Therapeutics (SION) stockholders that it is investigating the recent stock drop, with no specific figures, dates, or catalyst provided in the alert.
REGULATION | Aug 20, 2026, 02:22 AM UTC
L
SION - Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
SION - Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
EQUITY | Aug 17, 2026, 08:20 PM UTC
H
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ: SION ) announced topline clinical trial results from two nucleotide binding domain 1 (NBD1) stabilizer candidate programs targeting cystic fibros
GEOPOLITICS | Aug 10, 2026, 06:02 PM UTC
L
Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Monday. The Dow traded down 0.15% to 53,954.88 while the NASDAQ fell 0.18% to 26,645.53. The S&P 500 also rose, gaining, 0.
EARNINGS | Aug 10, 2026, 04:19 PM UTC
L
US Stocks Edge Lower; Monday.Com Shares Tumble After Q2 Results
U.S. stocks traded mostly lower this morning, with the Dow Jones index falling around 0.2% on Monday. Following the market opening Monday, the Dow traded down 0.16% to 53,949.06 while the NASDAQ fell 0.07% to 26,672.55.
EARNINGS | Aug 10, 2026, 01:40 PM UTC
L
SION - Sionna Therapeutics Reports Second Quarter 2026 Financial Results
SION - Sionna Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
SION Maintain Buy and $50 PT ahead of he upcoming Phase II Precision readout in the next 2-4 weeks @ GUGG
SION Maintain Buy and $50 PT ahead of he upcoming Phase II Precision readout in the next 2-4 weeks @ GUGG
EQUITY | Jul 27, 2026, 01:12 PM UTC
L
Sionna Therapeutics Insider Sold Shares Worth $3,854,281, According to a Recent SEC Filing
() -- Peter A. Thompson, Director, on July 07, 2026, sold 85,918 shares in Sionna Therapeutics (SION) for $3,854,281. Following the Form 4 filing with the SEC, Thompson has control over a total of 2,469,959 common shares
REGULATION | Jul 09, 2026, 08:54 PM UTC
L
Sionna Therapeutics Insider Sold Shares Worth $446,862, According to a Recent SEC Filing
() -- Jennifer Fitzpatrick, Chief Legal Officer, on July 06, 2026, sold 10,250 shares in Sionna Therapeutics (SION) for $446,862. SEC Filing: Copyright © 2026. All rights reserved. does not provide investment advice. Una
REGULATION | Jul 07, 2026, 08:42 PM UTC